INTROGEN THERAPEUTICS AWARDED ADDITIONAL ADVEXIN PATENT

Introgen Therapeutics has announced a patent that directly covers many of the special features of its Advexin molecular therapy, has been awarded by the U.S. Patent and Trademark Office.

The patent, U.S. Patent No. 6,905,873, is one of a family of patents that cover Advexin issued to the Board of Regents of The University of Texas System and exclusively licensed to Introgen.

In 1994, Introgen entered into a license agreement with The University of Texas System and M. D. Anderson Cancer Center, a component of The University of Texas System, and one of the largest academic cancer centers in the world.